Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$35.51 USD
+0.41 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $35.50 -0.01 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SUPN 35.51 +0.41(1.15%)
Will SUPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for SUPN
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics | SUPN Stock News
Supernus completes acquisition of Sage Therapeutics
Biogen rises as Alzheimer’s therapy drives Q2 beat
Supernus (SUPN) Receives Upgrade and Increased Price Target
Supernus (SUPN) Receives Upgrade from Cantor Fitzgerald